Regulation of cAMP and GSK3 signaling pathways contributes to the neuronal conversion of glioma

Jinsoo Oh, Yongbo Kim, Lihua Che, Jeong Beom Kim, Gyeong Eon Chang, Eunji Cheong, Seok-Gu Kang, Yoon Ha

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Glioma is the most malignant type of primary central nervous system tumors, and has an extremely poor prognosis. One potential therapeutic approach is to induce the terminal differentiation of glioma through the forced expression of pro-neural factors. Our goal is to show the proof of concept of the neuronal conversion of C6 glioma through the combined action of small molecules. We investigated the various changes in gene expression, cell-specific marker expression, signaling pathways, physiological characteristics, and morphology in glioma after combination treatment with two small molecules (CHIR99021, a glycogen synthase kinase 3 [GSK3] inhibitor and forskolin, a cyclic adenosine monophosphate [cAMP] activator). Here, we show that the combined action of CHIR99021 and forskolin converted malignant glioma into fully differentiated neurons with no malignant characteristics; inhibited the proliferation of malignant glioma; and significantly down-regulated gene ontology and gene expression profiles related to cell division, gliogenesis, and angiogenesis in small molecule–induced neurons. In vivo, the combined action of CHIR99021 and forskolin markedly delayed neurological deficits and significantly reduced the tumor volume. We suggest that reprogramming technology may be a potential treatment strategy replacing the therapeutic paradigm of traditional treatment of malignant glioma, and a combination molecule comprising a GSK3 inhibitor and a cAMP inducer could be the next generation of anticancer drugs.

Original languageEnglish
Article numbere0178881
JournalPloS one
Volume12
Issue number11
DOIs
Publication statusPublished - 2017 Nov 1

Fingerprint

Glycogen Synthase Kinase 3
forskolin
cyclic AMP
Colforsin
Glioma
Cyclic AMP
Gene expression
Molecules
Neurons
Tumors
neurons
gene expression
therapeutics
neoplasms
antineoplastic agents
Neurology
angiogenesis
prognosis
central nervous system
Ontology

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Oh, Jinsoo ; Kim, Yongbo ; Che, Lihua ; Kim, Jeong Beom ; Chang, Gyeong Eon ; Cheong, Eunji ; Kang, Seok-Gu ; Ha, Yoon. / Regulation of cAMP and GSK3 signaling pathways contributes to the neuronal conversion of glioma. In: PloS one. 2017 ; Vol. 12, No. 11.
@article{4538e476c1ca4cafae8537bb8bdd4577,
title = "Regulation of cAMP and GSK3 signaling pathways contributes to the neuronal conversion of glioma",
abstract = "Glioma is the most malignant type of primary central nervous system tumors, and has an extremely poor prognosis. One potential therapeutic approach is to induce the terminal differentiation of glioma through the forced expression of pro-neural factors. Our goal is to show the proof of concept of the neuronal conversion of C6 glioma through the combined action of small molecules. We investigated the various changes in gene expression, cell-specific marker expression, signaling pathways, physiological characteristics, and morphology in glioma after combination treatment with two small molecules (CHIR99021, a glycogen synthase kinase 3 [GSK3] inhibitor and forskolin, a cyclic adenosine monophosphate [cAMP] activator). Here, we show that the combined action of CHIR99021 and forskolin converted malignant glioma into fully differentiated neurons with no malignant characteristics; inhibited the proliferation of malignant glioma; and significantly down-regulated gene ontology and gene expression profiles related to cell division, gliogenesis, and angiogenesis in small molecule–induced neurons. In vivo, the combined action of CHIR99021 and forskolin markedly delayed neurological deficits and significantly reduced the tumor volume. We suggest that reprogramming technology may be a potential treatment strategy replacing the therapeutic paradigm of traditional treatment of malignant glioma, and a combination molecule comprising a GSK3 inhibitor and a cAMP inducer could be the next generation of anticancer drugs.",
author = "Jinsoo Oh and Yongbo Kim and Lihua Che and Kim, {Jeong Beom} and Chang, {Gyeong Eon} and Eunji Cheong and Seok-Gu Kang and Yoon Ha",
year = "2017",
month = "11",
day = "1",
doi = "10.1371/journal.pone.0178881",
language = "English",
volume = "12",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "11",

}

Regulation of cAMP and GSK3 signaling pathways contributes to the neuronal conversion of glioma. / Oh, Jinsoo; Kim, Yongbo; Che, Lihua; Kim, Jeong Beom; Chang, Gyeong Eon; Cheong, Eunji; Kang, Seok-Gu; Ha, Yoon.

In: PloS one, Vol. 12, No. 11, e0178881, 01.11.2017.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Regulation of cAMP and GSK3 signaling pathways contributes to the neuronal conversion of glioma

AU - Oh, Jinsoo

AU - Kim, Yongbo

AU - Che, Lihua

AU - Kim, Jeong Beom

AU - Chang, Gyeong Eon

AU - Cheong, Eunji

AU - Kang, Seok-Gu

AU - Ha, Yoon

PY - 2017/11/1

Y1 - 2017/11/1

N2 - Glioma is the most malignant type of primary central nervous system tumors, and has an extremely poor prognosis. One potential therapeutic approach is to induce the terminal differentiation of glioma through the forced expression of pro-neural factors. Our goal is to show the proof of concept of the neuronal conversion of C6 glioma through the combined action of small molecules. We investigated the various changes in gene expression, cell-specific marker expression, signaling pathways, physiological characteristics, and morphology in glioma after combination treatment with two small molecules (CHIR99021, a glycogen synthase kinase 3 [GSK3] inhibitor and forskolin, a cyclic adenosine monophosphate [cAMP] activator). Here, we show that the combined action of CHIR99021 and forskolin converted malignant glioma into fully differentiated neurons with no malignant characteristics; inhibited the proliferation of malignant glioma; and significantly down-regulated gene ontology and gene expression profiles related to cell division, gliogenesis, and angiogenesis in small molecule–induced neurons. In vivo, the combined action of CHIR99021 and forskolin markedly delayed neurological deficits and significantly reduced the tumor volume. We suggest that reprogramming technology may be a potential treatment strategy replacing the therapeutic paradigm of traditional treatment of malignant glioma, and a combination molecule comprising a GSK3 inhibitor and a cAMP inducer could be the next generation of anticancer drugs.

AB - Glioma is the most malignant type of primary central nervous system tumors, and has an extremely poor prognosis. One potential therapeutic approach is to induce the terminal differentiation of glioma through the forced expression of pro-neural factors. Our goal is to show the proof of concept of the neuronal conversion of C6 glioma through the combined action of small molecules. We investigated the various changes in gene expression, cell-specific marker expression, signaling pathways, physiological characteristics, and morphology in glioma after combination treatment with two small molecules (CHIR99021, a glycogen synthase kinase 3 [GSK3] inhibitor and forskolin, a cyclic adenosine monophosphate [cAMP] activator). Here, we show that the combined action of CHIR99021 and forskolin converted malignant glioma into fully differentiated neurons with no malignant characteristics; inhibited the proliferation of malignant glioma; and significantly down-regulated gene ontology and gene expression profiles related to cell division, gliogenesis, and angiogenesis in small molecule–induced neurons. In vivo, the combined action of CHIR99021 and forskolin markedly delayed neurological deficits and significantly reduced the tumor volume. We suggest that reprogramming technology may be a potential treatment strategy replacing the therapeutic paradigm of traditional treatment of malignant glioma, and a combination molecule comprising a GSK3 inhibitor and a cAMP inducer could be the next generation of anticancer drugs.

UR - http://www.scopus.com/inward/record.url?scp=85034758111&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85034758111&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0178881

DO - 10.1371/journal.pone.0178881

M3 - Article

VL - 12

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 11

M1 - e0178881

ER -